NCT01979887|Completed
Loading search results
Sponsor study identifier
observational
75
2 countries
2
Study Start
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2014
Actual (reported)Study Completion
July 2014
Actual (reported)This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
November 4, 2013
Actual (reported)November 8, 2013
Actual (reported)July 2014
Actual (reported)July 2014
Actual (reported)Meibum Quality Score in the Study Eye as Assessed by the Investigator Using a 4-Point Scale
Day 22
Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
Meibum expression as per protocol. No investigational drug is administered in this study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Participants characterized as with or without Meibomian Gland Dysfunction.
Houston, Texas, United States
London, United Kingdom
Nguyen A, Naidoo KK, Ajouz L, Xu X, Zhao C, Robinson MR, Borchman D. Changes in Human Meibum Lipid Composition Related to the Presence and Severity of Meibomian Gland Dysfunction. J Ocul Pharmacol Ther. 2024 Nov;40(9):562-570. doi: 10.1089/jop.2024.0063. Epub 2024 Aug 16.
Ajouz L, Hallak J, Naik R, Nguyen A, Zhao C, Robinson MR, Nichols KK. Evaluation of the Impact of Meibomian Gland Dysfunction Using a Novel Patient-Reported Outcome Instrument. J Ocul Pharmacol Ther. 2024 Jan-Feb;40(1):48-56. doi: 10.1089/jop.2023.0080. Epub 2023 Nov 1.
Tears
Medical Director
Allergan
75 participants (actual enrollment reported by the registry).
First Submitted
November 4, 2013
First Posted
November 8, 2013
Study Start
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Ajouz L, Nguyen A, Zhao C, Robinson MR, Nichols KK. Exploring Signs and Symptoms Associated with Meibomian Gland Dysfunction for Use as Clinical Trial Endpoints. J Ocul Pharmacol Ther. 2023 Nov;39(9):611-621. doi: 10.1089/jop.2023.0064. Epub 2023 Aug 29.
Nagar S, Ajouz L, Nichols KK, Kumar S, Zhao C, Naidoo KK, Robinson MR, Borchman D. Relationship Between Human Meibum Lipid Composition and the Severity of Meibomian Gland Dysfunction: A Spectroscopic Analysis. Invest Ophthalmol Vis Sci. 2023 Jul 3;64(10):22. doi: 10.1167/iovs.64.10.22.
Primary Completion
July 2014
Actual (reported)Study Completion
July 2014
Actual (reported)Last Updated
August 15, 2014
Record last verified: 2014-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: